Proteomics International Laboratories Ltd (ASX:PIQ)

Australia flag Australia · Delayed Price · Currency is AUD
0.230
+0.010 (4.55%)
Apr 29, 2026, 3:24 PM AEST
-39.47%
Market Cap 37.99M
Revenue (ttm) 3.21M
Net Income (ttm) -9.66M
Shares Out 165.18M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 89,675
Average Volume 438,415
Open 0.220
Previous Close 0.220
Day's Range 0.220 - 0.235
52-Week Range 0.205 - 0.860
Beta -0.24
RSI 39.76
Earnings Date May 25, 2026

About ASX:PIQ

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has comple... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PIQ
Full Company Profile

Financial Performance

In fiscal year 2025, ASX:PIQ's revenue was 3.31 million, an increase of 1.34% compared to the previous year's 3.27 million. Losses were -8.11 million, 27.3% more than in 2024.

Financial Statements

News

Proteomics International Laboratories Transcript: Bell Potter Healthcare Conference 2025

Four first-in-class diagnostic tests are being commercialized, with PromarkerD live in Australia and California and reimbursement pricing imminent. The company is focused on expanding launches, building strategic partnerships, and leveraging its digital platform, with no planned headcount increase for 2026.

5 months ago - Transcripts